

<b>NCT ID</b>	NCT03785249
<b>Title</b>	Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2018-12-24
<b>Location</b>	Alabama, United States Alaska, United States Arizona, United States California, United States Colorado, United States Connecticut, United States Delaware, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Puerto Rico
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	afatinib, cetuximab, MRTX849, Pembrolizumab
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT06066424
<b>Title</b>	Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
<b>Phase</b>	Phase 1
<b>Date Added</b>	2023-10-04
<b>Location</b>	Texas, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Recruiting
<b>Drugs</b>	Cyclophosphamide, Fludarabine Phosphate, Rimiducid, TROP2-CAR-NK Cells
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	PG545 (pixatimod) in combination with nivolumab

<b>Title</b>	PG545 (pixatimod) in combination with nivolumab
<b>Phase</b>	Phase 1
<b>Date Added</b>	2019-04-26
<b>Location</b>	
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT06841159
<b>Title</b>	Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1?Chemotherapy and Target Therapy for Metastatic Colorectal Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2025-03-25
<b>Location</b>	China
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT05349890
<b>Title</b>	Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
<b>Phase</b>	Phase 1
<b>Date Added</b>	2022-04-27
<b>Location</b>	Oregon, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	CDX-1140, Pembrolizumab, Keytruda
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT02600949
<b>Title</b>	Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
<b>Phase</b>	Phase 1
<b>Date Added</b>	2015-11-09
<b>Location</b>	Texas, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Enrolling by invitation
<b>Drugs</b>	imiquimod, Pembrolizumab, Sotigalimab, Synthetic Tumor-Associated Peptide Vaccine Therapy
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT03568058
<b>Title</b>	Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
<b>Phase</b>	Phase 1
<b>Date Added</b>	2018-06-26
<b>Location</b>	California, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No

<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Pembrolizumab, personalized vaccine, Keytruda
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT04096417
<b>Title</b>	Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
<b>Phase</b>	Phase 2
<b>Date Added</b>	2019-09-19
<b>Location</b>	Arizona, United States Georgia, United States Minnesota, United States North Carolina, United States Tennessee, United States Wisconsin, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Pemigatinib
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT04014530
<b>Title</b>	Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study
<b>Phase</b>	Phase 1
<b>Date Added</b>	2019-07-10
<b>Location</b>	Netherlands
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Ataluren + Pembrolizumab, Keytruda
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT03519412
<b>Title</b>	Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
<b>Phase</b>	Phase 2
<b>Date Added</b>	2018-05-09
<b>Location</b>	Italy
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	pembrolizumab (treatment), temozolomide (induction),, Keytruda, Temodar
<b>Tags</b>	MSS/ MMRp